multiforme in Medical News

European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors

... of patients with newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and ... adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as ... 65 years. In newly diagnosed glioblastoma multiforme the most common adverse reactions in clinical ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

... will be forthcoming. About Glioblastoma multiforme Glioblastoma multiforme (GBM) is the most common and most advanced form ... to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of ...

Cancer Mortality Increases With Cancer Cell Replikin Count

... mortality after 5 years.  Glioblastoma multiforme and non-small-cell lung cancer, the two cancer ... respectively).   The count in Glioblastoma multiforme is 18 times higher than the counts in prostate ... in the laboratory in the case of glioblastoma multiforme brain cancer cells in tissue culture*. The ...

Some Immature Brain Cells May Promote Tumors

... used tumor tissue from people with glioblastoma multiforme to develop a cell that ignored the effects of two ... growth. The team then analyzed 54 glioblastoma multiforme tumors and found that one in five (20 percent) ... neuronal stem-like starter cells in glioblastoma multiforme and other cancers, and give us a strong rationale ...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... kinase inhibitor, is cytotoxic to glioblastoma multiforme cell lines (Abstract No. 178). Activity was also demonstrated in vivo in a glioblastoma multiforme xenograft model. Evidence presented here ... of MP470 against glioblastoma multiforme cells is synergistic with radiation. ...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

... a Phase II trial as a potential new treatment for recurrent glioblastoma multiforme (GBM), a deadly form of brain cancer. The company also reported that ... drug status and fast track designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma by the U.S. Food and Drug Administration. A ...

NCCN Updates Guidelines for Central Nervous System (CNS) Cancers

... to use bevacizumab as a single agent for recurrent glioblastoma multiforme in CNS cancers, the integration of a patient's Karnofsky Performance ... change in the updated NCCN Guidelines for patients with glioblastoma multiforme is the integration of a patient's Karnofsky Performance Status (KPS) score ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

... the effects of Neuradiab(TM) on Patients with Newly Diagnosed Glioblastoma multiforme (GBM). The SNO meeting is being held in Lake Las Vegas, Nevada from ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...

Bradmer to present at Rodman & Renshaw Healthcare Conference

... therapy to the current standard of care for newly diagnosed glioblastoma multiforme (GBM). The presentation will take place on Wednesday, November 12th at ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab ...

JCI online early table of contents: Aug. 1, 2008

... death improves cancer therapy efficacy Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely ... to individuals with GBM. TITLE: Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of ...

Sen. Kennedy Up and Walking After Brain Tumor Surgery

... Some cancer specialists said the tumor appears likely to be a glioblastoma multiforme -- a serious and tough-to-remove type -- because other kinds of brain ... more than doubled progression-free survival in patients with glioblastoma multiforme tumors -- from 6.4 months to 16.6 months. Discussing Kennedy's ...

Bradmer receives FDA approval to proceed with Phase III clinical trial

... trial evaluating Neuradiab(TM) as a front-line therapy for glioblastoma multiforme (GBM), the most common and advanced form of primary brain cancer. To ... antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and advanced form of brain cancer. Neuradiab(TM) ...

Sen. Kennedy's Brain Tumor Surgery Called a 'Success'

... Some cancer specialists said the tumor appears likely to be a glioblastoma multiforme -- a serious and tough-to-remove type -- because other kinds of brain ... more than doubled progression-free survival in patients with glioblastoma multiforme tumors -- from 6.4 months to 16.6 months. Discussing Kennedy's ...

Vaccine May Boost Survival of Brain Cancer Patients

... more than doubled progression-free survival in patients with glioblastoma multiforme tumors. Kennedy was diagnosed last month with a malignant glioma, a class ... deaths in the United States. Current therapies for glioblastoma multiforme (GBM) tumors include surgery, chemotherapy and radiation. The ...

Bradmer announces 2008 first quarter operational and financial results

... and temozolomide in 760 patients with newly diagnosed glioblastoma multiforme (GBM). The randomized trial is expected to be conducted at leading brain ... plan: - Continue the activation and training of glioblastoma multiforme treatment centers across the U.S. - Submit final clinical ...

Bradmer announces 2007 fourth quarter and fiscal year operational and financial results

... and temozolomide in 760 patients with newly diagnosed glioblastoma multiforme (GBM). The randomized trial is expected to be conducted at leading brain ... plan: - Continue the activation and training of glioblastoma multiforme treatment centers across the U.S. - Submit final clinical ...

Bradmer announces additions to Scientific Advisory Board

... patient practice and frontline experience in the treatment of glioblastoma multiforme will benefit our entire team at Bradmer," said Alan M. Ezrin, Ph.D., ... involvement of the preeminent thought leaders in the study of glioblastoma multiforme from the leading brain cancer centers in North America and Europe," added ...

Common virus may help doctors treat deadly brain tumors

... association with the tumors but also saw that patients with glioblastoma multiforme had detectable virus in their bloodstreams, where the comparative group ... said. Because HCMV is present in such a large number of glioblastoma multiforme patients, the development of an effective treatment that targets the virus ...

Clinical trial evaluating brain cancer vaccine is underway at NYU

... NYU. Despite surgery and chemotherapy, patients with glioblastoma multiforme brain cancer typically survive about 15 months. Even if only a small ... will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery ...

National Cancer Coalition Announces Angel Grant Recipients

... of Chicago's Comer Children's Hospital. His Angel Grant will be used to further his investigations of the biology of pediatric Glioblastoma multiforme (GBM) brain tumors and their treatment. The National Cancer Coalition implemented its Angel Grant program to provide seed funding to ...

Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved

... in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an ...

Amgen's Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To $1.29

... The Company provided an update on several of its clinical programs: AMG 102: In Phase 2 studies, limited efficacy was seen in glioblastoma multiforme and renal cell carcinoma when AMG 102 was administered in monotherapy, but the effect size was not large enough to warrant moving forward with ...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

... in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme (GBM) patients. Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain ...

Most common brain cancer may start in neural stem cells

... are highly plastic. If a treatment blocks one path of action, they may learn other ways to grow," Zhu says. That helps explain why glioblastoma multiforme returns in drug-resistant forms. Research details: Zhu's team conducted a series of experiments using mice engineered to have a p53 mutation ...

Most common brain cancer may originate in neural stem cells

... are highly plastic. If a treatment blocks one path of action, they may learn other ways to grow," Zhu says. That helps explain why glioblastoma multiforme returns in drug-resistant forms. Research details: Zhu's team conducted a series of experiments using mice engineered to have a p53 mutation ...

Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer

... Carcinoma (Abstract #e15684)" and "A Phase 2a Study of Light-Activated Talaporfin Sodium in Patients with Primary or Recurrent Glioblastoma multiforme (Abstract #e13026)." About Aptocine Aptocine (talaporfin sodium) is a water-soluble drug activated by an included small, single-use, ...

Delivering Chemo Directly Into Brain Tumors Shows Promise

... and left parietal syndrome, neurological issues caused by damage to the brain. The patients had two types of tumors: 10 had a glioblastoma multiforme (GBM), an invasive and fast-growing tumor, while six had anaplastic glioma. "Topotecan by convection-enhanced delivery has significant anti-tumor ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

... 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer: - Prepared and submitted the Company's drug manufacturing data package and ...

Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports

... fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure and GI perforation. Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe ...

Brain tumor treatment may increase number of cancer stem-like cells

... insight into the molecular mechanisms that enable cancer stem-like cells to escape cytotoxic treatment and repopulate the tumor. Glioblastoma multiforme is the most prevalent and aggressive form of primary brain tumor and is notoriously resistant to standard therapies. Dr. Eric Holland, from Memorial ...

Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)

... fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and GI perforation. Bullous dermatologic reactions (e.g., erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon re-challenge. Several post marketing reports ...

PEGASYS(R) Proven Effective as Hepatitis C Treatment for Latino Patients, According to Article in The New England Journal of Medicine

... use of PEGASYS therapy, with and without ribavirin, include hearing impairment, hearing loss, serious skin reactions, including erythema multiforme major, and infections (bacterial, viral and fungal). About Roche Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. ...

Gene therapy eliminates brain tumors through selective recruitment of immune cells

... T cells. This caused the regression of the brain tumors and increased survival time by six months in experimental brain tumor models. Glioblastoma multiforme is the most aggressive type of brain tumor, with only five percent of patients surviving five years following diagnosis. While new drugs have had ...

Studies show novel device may enhance chemotherapy treatment in brain tumors

... a pilot clinical trial that showed the device enhanced the efficacy of standard chemotherapy (temozolomide) treatment in newly-diagnosed glioblastoma multiforme (GBM) patients. When used in combination with standard chemotherapy, the Novo-TTF, a non-invasive medical device that uses low intensity alternating ...

Bradmer announces 2008 third quarter operational and financial results

... at http://www.sedar.com . About Neuradiab(TM) Neuradiab is a monoclonal antibody, conjugated to radioactive iodine, used to treat glioblastoma multiforme (GBM), the most common and most advanced form of brain cancer. Neuradiab delivers tumor-killing radiation specifically to residual brain tumor cells ...

The Cancer Genome Atlas reports first results, Johns Hopkins Kimmel Cancer Center collaborates

... investigators from seven cancer centers and research institutions throughout the country, analyzed 601 genes in tumor samples from 91 glioblastoma multiforme (GBM) patients. Investigators at the Johns Hopkins Kimmel Cancer Center and University of Southern California, members of the TCGA team, studied ...

Genetic Mutations Linked to Deadly Cancers

... Velculescu, an assistant professor of oncology at Johns Hopkins University, and colleagues studied 20,000 genes from 22 patients with glioblastoma multiforme (GBM), the same type of cancer diagnosed in Sen. Edward Kennedy earlier this year. "We found that a typical GBM contains approximately 60 genetic ...

Overcoming inhibitors of cell death improves cancer therapy efficacy

... Individuals with glioblastoma multiforme (GBM), one of the most aggressive types of brain tumor, have an extremely poor prognosis. Although pre-clinical studies indicated therapeutics ...

Brain Cancer Vaccine's Immune Response Key to Outcomes

... finds TUESDAY, July 15 (HealthDay News) -- An in-trial dendritic cell vaccine that fights malignant brain tumors called glioblastoma multiforme (GBM) may help boost a patient's immunity response and improve the outcome, a new report says. An article in the July 15 issue of Cancer ...

Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes

... AT 12:01 A.M. EDT) Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a patient's immune response and clinical outcome, according to an article in the July 15 ...